Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Common Equity: 2022-2024

Historic Common Equity for Immunocore Holdings (IMCR) over the last 3 years, with Dec 2024 value amounting to $360.7 million.

  • Immunocore Holdings' Common Equity rose 4.96% to $396.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.6 million, marking a year-over-year increase of 4.96%. This contributed to the annual value of $360.7 million for FY2024, which is 2.20% down from last year.
  • According to the latest figures from FY2024, Immunocore Holdings' Common Equity is $360.7 million, which was down 2.20% from $368.8 million recorded in FY2023.
  • In the past 5 years, Immunocore Holdings' Common Equity registered a high of $368.8 million during FY2023, and its lowest value of $338.9 million during FY2022.
  • Over the past 3 years, Immunocore Holdings' median Common Equity value was $360.7 million (recorded in 2024), while the average stood at $356.2 million.
  • In the last 5 years, Immunocore Holdings' Common Equity grew by 8.83% in 2023 and then declined by 2.20% in 2024.
  • Yearly analysis of 3 years shows Immunocore Holdings' Common Equity stood at $338.9 million in 2022, then climbed by 8.83% to $368.8 million in 2023, then decreased by 2.20% to $360.7 million in 2024.